Sanjay Nigam, MD
Psychiatry · Maryville, ILNPI 1942278973
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,165 of the $114,484 with a category attached, or 63.0%. Johnson & Johnson accounts for 70.2% of it on its own, with 33 other manufacturers making up the rest. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 566 payments — averaging $202.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$80K
- AbbVie$29K
- Supernus Pharmaceuticals, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$573
- Otsuka America Pharmaceutical, Inc.$378
- Teva Pharmaceuticals USA, Inc.$376
- plus $2K from 28 others
Across 20 payments — averaging $2557.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$32K
- Acadia Pharmaceuticals Inc$17K
- Orexo US, Inc.$3K
What the payments were for
- Consulting fees$21,66519%
- Speaking & faculty fees$72,16563%
- Travel & lodging$10,89110%
- Food & beverage$9,5248%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 153 | $80,383 |
| AbbVie(2 entities) | 193 | $29,272 |
| Supernus Pharmaceuticals, Inc. | 48 | $1,170 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $573 |
| Otsuka America Pharmaceutical, Inc. | 21 | $378 |
| Teva Pharmaceuticals USA, Inc. | 19 | $376 |
| Lundbeck LLC | 12 | $261 |
| Alkermes, Inc. | 10 | $215 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Axsome Therapeutics, Inc. | 10 | $196 |
| E.r. Squibb & Sons, L.L.C. | 5 | $185 |
| Neurocrine Biosciences, Inc. | 9 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $149 |
| Vanda Pharmaceuticals Inc. | 4 | $111 |
| Livanova USA, Inc. | 5 | $104 |
| Orexo US, Inc. | 2 | $85 |
| Indivior Inc. | 4 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Ironshore Pharmaceuticals Inc. | 3 | $67 |
| Neuronetics, Inc. | 5 | $61 |
| Biogen | 3 | $56 |
| Tris Pharma Inc | 2 | $40 |
| Almatica Pharma LLC | 2 | $39 |
| Merck | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $34 |
| Lilly USA, LLC | 1 | $33 |
| Neos Therapeutics, LP | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,484 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $102,769 |
| NuplazidPimavanserin Tartrate | 13 | $71,831 |
| Invega SustennaPaliperidone Palmitate | 21 | $59,079 |
| VraylarCariprazine Hcl | 26 | $46,826 |
| Paliperidone ErPaliperidone | 41 | $28,685 |
| SublocadeBuprenorphine | 13 | $27,214 |
| TrintellixVortioxetine Hydrobromide | 31 | $22,554 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $21,408 |
| SpravatoEsketamine Hcl | 18 | $20,667 |
| Aripiprazole | 187 | $16,018 |
| Atomoxetine Hcl | 44 | $7,237 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 44 | $6,468 |
| Memantine Hcl | 82 | $6,188 |
| Divalproex Sodium ErDivalproex Sodium | 80 | $5,999 |
| Quetiapine Fumarate | 301 | $5,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $165 | $102,76912 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $80,383 | $79,74639 claims |
| Acadia Pharmaceuticals IncNuplazid | $20 | $71,83113 claims |
| AbbVieVraylar | $29,272 | $46,82626 claims |
| Indivior Inc.Sublocade | $76 | $27,21413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $149 | $22,55431 claims |
| Axsome Therapeutics, Inc.Auvelity | $196 | $21,40816 claims |
| Almatica Pharma LLCSertraline Hcl | $39 | $3,159276 claims |
| Lilly USA, LLCOlanzapine | $33 | $2,542103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Maryville
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
- Abid NazeerOak Brook$228K
- Nitin ThaparOrland Park$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.